MaryBeth Dorr
Justus-Liebig-Universität Gießen(DE)VenatoRx Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Urinary Tract Infections Management, Bacterial Identification and Susceptibility Testing, Antimicrobial Resistance in Staphylococcus
Most-Cited Works
- → Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections(2003)233 cited
- → Cefepime–Taniborbactam in Complicated Urinary Tract Infection(2024)101 cited
- → Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection(2024)15 cited
- Dalbavancin pharmacokinetics in subjects with mild or moderate hepatic impairment(2003)